A patient receives cancer treatments with Avastin, or bevacizumab, in 2005. At first touted for excellent results, the cancer drug ultimately was found to have no effect on overall survival or the patients’ quality of life.
A patient receives cancer treatments with Avastin, or bevacizumab, in 2005. At first touted for excellent results, the cancer drug ultimately was found to have no effect on overall survival or the patients’ quality of life. David Grubbs AP file
A patient receives cancer treatments with Avastin, or bevacizumab, in 2005. At first touted for excellent results, the cancer drug ultimately was found to have no effect on overall survival or the patients’ quality of life. David Grubbs AP file